Saad et al. introduced Deep-CT, a deep learning ensemble model predicting overall and progression-free survival in EGFR/ALK-negative NSCLC patients undergoing immune checkpoint inhibitor (ICI) therapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.